News and Announcements
Dr Martin Cross Appointed Non-Executive Director at Oncosil
- Published February 27, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
OncoSil Medical Limited (ASX: OSL) is pleased to announce the appointment of Mr Lawrence Gozlan as an independent Non-executive Director of the Company, effective from today. Mr Gozlan is a highly experienced and successful biotechnology industry professional, with particular expertise in investment management and corporate advice in the life science sector.
Mr Gozlan is currently a Director of Prana Biotechnology (ASX: PBT), a Director of Ausbiotech Ltd and a number of private healthcare companies. He holds a Bachelor of Science with Honours in microbiology and immunology from the University of Melbourne.
OncoSil Medical chairman Martin Rogers said:
“On behalf of the board of directors it is with great pleasure that we welcome the appointment of Lawrence Gozlan as a non-exec director. His proven experience and track record as a biotech investment manager will be invaluable to the Company, and we are confident his input and contribution will further strengthen the board as we continue to unlock value for investors.”
OncoSil Medical Ltd (OncoSil Medical) is a clinical-stage Australian biotechnology company with the aim is to provide new technologies for safer medical radiation treatments. OncoSil Medical’s lead product is OncoSil™ with the first target indication being pancreatic cancer.
Company Updates
Forget Startups: Why Magnetic Alliance is Betting on “Boring” Mid-Market Turnarounds
While Australia’s venture capital scene spent years chasing unprofitable tech startups and speculative high-growth plays, Mark Lim was quietly taking a radically different path. The Managing Partner of Magnetic Alliance Capital sees the nation’s richest investment opportunities hiding in plain sight: inside thousands of unglamorous, profitable, but operationally sluggish mid-market businesses. Speaking on Wholesale Investor’s […]
The asset class where the market has no vote
Litigation funding returns are decided in a courtroom, not a cycle. Knightsbridge’s Head of Capital is careful to call that a different risk rather than a lower one, and his answer to it is spread, not concentration. Most alternative assets still answer to something. Property answers to rates. Private credit answers to defaults. Even the […]
The listing fee vendors pay whether the house sells or not
Australia’s property portals collect more than $2 billion a year while national listings sit flat. An Australian-built AI platform is targeting the economics, not just the interface. An Australian vendor listing a home pays a vendor-paid advertising fee on top of agency commission. Rama Dwarapudi, Founder and Chief Executive Officer of RealSearch, puts a typical […]
Backed By Leading Investment Groups and Family Offices
